Browse the corpus

Drug-induced lupus is an autoimmune syndrome precipitated by exposure to specific medications and characterized by clinical and serologic features that resemble idiopathic systemic lupus erythematosus. Common manifestations include arthralgia, myalgia, fever, serositis, and fatigue, while renal and central nervous system involvement occur less frequently than in primary lupus. Serologic evaluation typically demonstrates a positive antinuclear antibody test, often with antihistone antibodies, supporting diagnostic differentiation. Withdrawal of the offending medication usually leads to symptom resolution, distinguishing drug-induced lupus as a reversible condition. The increasing use of biologics, targeted therapies, and cancer immunotherapies has expanded the spectrum of implicated agents, underscoring the need for heightened clinical awareness and accurate identification. Course participants gain practical knowledge to identify medications associated with drug-induced lupus, distinguish clinical and laboratory features of drug-induced lupus from those of idiopathic systemic lupus erythematosus, and select appropriate diagnostic testing. Clinicians develop skills in timely diagnosis, medication reconciliation, and evidence-based management, including decisions regarding drug discontinuation and adjunctive therapy when indicated. Emphasis is placed on reducing unnecessary testing and preventing delays in care. Collaboration within an interprofessional healthcare team, including pharmacists, nurses, primary care clinicians, and specialists, is highlighted as enhancing medication surveillance, diagnostic accuracy, and care coordination. Team-based communication supports early recognition, appropriate intervention, and improved patient outcomes while minimizing morbidity associated with delayed or missed diagnoses. Objectives: Identify medications most commonly associated with drug-induced lupus, including newer biologic and immunotherapy agents. Differentiate drug-induced lupus from idiopathich systemic lupus erythematosus based on clinical presentation and serologic findings. Implement evidence-based strategies for discontinuing causative drugs and managing symptoms in patients with drug-induced lupus.

Identify medications most commonly associated with drug-induced lupus, including newer biologic and immunotherapy agents. Differentiate drug-induced lupus from idiopathich systemic lupus erythematosus based on clinical presentation and serologic findings. Implement evidence-based strategies for discontinuing causative drugs and managing symptoms in patients with drug-induced lupus. Collaborate effectively across disciplines (pharmacy, nursing, rheumatology, dermatology, and primary care) to ensure early recognition, patient education, and coordinated management of drug-induced lupus. Access free multiple choice questions on this topic.

Drug-induced lupus (DIL) is an acquired autoimmune condition in which exposure to certain medications leads to lupus-like manifestations. Since the first reports of a lupus-like rash with sulfadiazine exposure in the 1940s, more than 100 drugs have been implicated.[1] Well-established agents include hydralazine, procainamide, isoniazid, minocycline, and quinidine, all of which remain clinically relevant. Patients with DIL typically present with arthralgia, myalgia, fever, and serositis, whereas severe organ involvement is less common than in idiopathic systemic lupus erythematosus (SLE). Symptoms usually resolve with withdrawal of the offending agent, although corticosteroids or antimalarials may be required in persistent cases.[1] More recent pharmacovigilance studies confirm that biologic therapies, particularly tumor necrosis factor-α inhibitors, account for a large proportion of reported cases.[2] In addition, immune checkpoint inhibitors have been associated with both cutaneous and systemic manifestations.[3] Given the diverse array of traditional and emerging drugs associated with DIL, clinicians must maintain awareness across multiple therapeutic classes to ensure timely recognition and management.

A wide range of medications has been implicated in the development of DIL, with more than 100 agents across more than 10 therapeutic categories reported. Some drugs have a well-documented and consistent association, while others are supported primarily by isolated case reports. Common categories include antiarrhythmics, antihypertensives, antibiotics, antiepileptics, antipsychotics, anti-inflammatory agents, antithyroid agents, and diuretics. Individual drugs vary in their associated risk of DIL (see Table. Drugs Implicated in DIL According to Risk Category).[4] Among the best-established agents are procainamide and hydralazine, both of which carry the highest documented risks of inducing DIL. Historical estimates suggest that up to 20% of patients on long-term procainamide and 5% to 10% of those on hydralazine may develop lupus-like symptoms.[5] Other medications with strong evidence include isoniazid, rifampin, minocycline, quinidine, phenytoin, methyldopa, chlorpromazine, penicillamine, carbamazepine, ethosuximide, propylthiouracil, sulfasalazine, and interferon-α. However, many of these drugs are now used less frequently than in the past.[6] More recently, biologic therapies have expanded the spectrum of medications implicated in the development of DIL. All tumor necrosis factor-α inhibitors (etanercept, infliximab, adalimumab, golimumab, and certolizumab) have been linked to lupus-like presentations, typically manifesting as mild to moderate disease that improves with drug withdrawal.[7] Additionally, several herbal products, including alfalfa sprouts, echinacea, and melatonin, have been associated with lupus flares in susceptible individuals.[8] Multiple classes of medications have been implicated in subacute cutaneous drug-induced lupus. Among the most frequently associated are proton pump inhibitors, chemotherapeutic drugs, and biologic therapies—particularly anti-tumor necrosis factor-α inhibitors.[9] Immune checkpoint inhibitors, such as programmed cell death protein-1 and programmed cell death ligand-1 inhibitors, can cause immune-related adverse events, including subacute cutaneous lupus erythematosus and SLE.[3]

Multiple classes of medications have been implicated in subacute cutaneous drug-induced lupus. Among the most frequently associated are proton pump inhibitors, chemotherapeutic drugs, and biologic therapies—particularly anti-tumor necrosis factor-α inhibitors.[9] Immune checkpoint inhibitors, such as programmed cell death protein-1 and programmed cell death ligand-1 inhibitors, can cause immune-related adverse events, including subacute cutaneous lupus erythematosus and SLE.[3] These events are likely underreported and represent less than 1% of all immune-related adverse events (irAEs).[3] Drug-induced lupus resulting from immune checkpoint inhibitors is a rare subtype of irAEs, most commonly associated with anti-programmed cell death (PD)-1 and PD-L1 inhibitors (eg, pembrolizumab and nivolumab) and less frequently with anti-cytotoxic T-lymphocyte–associated protein 4 inhibitors (eg, ipilimumab). Clinical features and antibody profiles may vary with the offending agent, underscoring the importance of considering both classic and novel agents when evaluating suspected cases of DIL. Table Table. Drugs Implicated in DIL According to Risk Category.

DIL is estimated to account for up to 10% of new lupus cases annually.[10] In the United States, approximately 15,000 to 30,000 cases occur each year. Compared with SLE, DIL affects a higher proportion of men and tends to occur in older individuals.[11] An analysis of more than 12,000 DIL case reports in the World Health Organization pharmacovigilance database found that affected patients had a median age of 49 years, a female-to-male ratio of approximately 4:1, and a median latency of roughly 6 months from drug initiation to symptom onset. In this cohort, more than half of the events were classified as serious, and the most frequently implicated medications were infliximab, adalimumab, etanercept, procainamide, and hydralazine.[12]

The mechanisms underlying DIL are not fully understood, but multiple factors contribute to disease pathogenesis. Genetic predisposition, including variations in drug metabolism (eg, acetylator status) and immunogenetic traits, influences the risk of developing DIL. Proposed pathogenic mechanisms include abnormal oxidative metabolism, cytotoxic metabolites, drugs that act as haptens, nonspecific lymphocyte activation, impaired central tolerance, thymic abnormalities, checkpoint inhibition (cytotoxic T-lymphocyte–associated protein 4, PD-1), altered innate immunity (eg, neutrophil extracellular trap formation), and epigenetic changes, such as DNA methylation defects.[13][14] Collectively, these processes lead to immune dysregulation, ultimately resulting in autoantibody production and organ-specific injury.[15] The risk of developing DIL is influenced by the specific medication involved. For example, hydralazine-induced lupus is associated with higher daily doses (>200 mg/day) and greater cumulative drug exposure. Host susceptibility factors for hydralazine-induced DIL include female sex, slow acetylation, and immunogenetic variants such as human leukocyte antigen–DR4 and complement C4 null alleles. Procainamide-induced lupus is similarly associated with slow acetylor status. Slow acetylators tend to accumulate parent compounds such as procainamide and hydralazine, thereby increasing their risk of developing DIL. The pathophysiology of immune checkpoint inhibitor therapy-associated DIL differs from that of traditional oral small molecules. These agents may disrupt immune tolerance and trigger autoimmunity.[3] In patients with idiopathic SLE, dysregulation of the PD-1 pathway is associated with T-cell activation, abnormal B-cell proliferation, and inflammatory activation. Abnormalities in TAM receptors and the aryl hydrocarbon receptor may further disrupt the regulation of the PD-1 pathway in idiopathic SLE.[3] Hence, exposure to these medications may result in the onset of DIL, with mechanisms similar to those seen with idiopathic SLE.

Cutaneous lesions in DIL exhibit histopathologic features identical to those seen in idiopathic cutaneous lupus. Typical findings include vacuolar or interface dermatitis with apoptotic (dyskeratotic) keratinocytes, epidermal atrophy, superficial perivascular and often periadnexal lymphohistiocytic infiltrates, and increased dermal mucin.[16][17] Direct immunofluorescence (DIF) is frequently positive, demonstrating immunoglobulin G deposition along the dermo-epidermal junction. While these features strongly support a diagnosis of lupus, routine histology and DIF do not reliably distinguish DIL from idiopathic disease. Therefore, clinicopathologic correlation paired with a thorough medication history remains essential.[1]

DIL encompasses a broad clinical spectrum that mimics idiopathic SLE but typically lacks the major organ-threatening complications of idiopathic disease. Symptoms most often develop after weeks to months of drug exposure, although delayed presentations beyond 1 year have been reported, particularly with hydralazine and procainamide.[18] This variable latency complicates recognition, mainly because DIL shares many clinical features with idiopathic SLE. Despite these similarities, DIL usually follows a milder clinical course. Severe renal, neurologic, or vasculitic involvement remains uncommon, distinguishing DIL from its idiopathic counterpart.[19] Constitutional and musculoskeletal symptoms typically dominate the clinical presentation. Arthralgia or arthritis occurs in most patients, often representing the earliest symptom, and is frequently accompanied by fever, myalgia, fatigue, and weight loss.[1] Cutaneous manifestations are less common than in idiopathic SLE; however, subacute cutaneous lupus erythematosus (SCLE) is frequently drug-induced, accounting for up to one-third of SCLE cases. These skin eruptions are strongly associated with anti-Ro/Sjögren syndrome–associated autoantibodies (anti-Ro/SSA) and typically present as photodistributed annular or psoriasiform rashes.[20] In contrast, chronic discoid lesions, scarring alopecia, and mucosal ulcers are distinctly uncommon in DIL. Serositis is another hallmark feature of DIL, with pleuritis occurring more commonly than pericarditis.[21] In procainamide-induced lupus, pleuritis develops in nearly half of affected patients, whereas pericarditis is less frequent and rarely severe. Major organ involvement is uncommon; lupus nephritis and neuropsychiatric lupus are seldom drug-induced, though hydralazine and minocycline have been linked to occasional cases.[22] Hematologic abnormalities, such as leukopenia or anemia, may occur but are typically mild.

Serositis is another hallmark feature of DIL, with pleuritis occurring more commonly than pericarditis.[21] In procainamide-induced lupus, pleuritis develops in nearly half of affected patients, whereas pericarditis is less frequent and rarely severe. Major organ involvement is uncommon; lupus nephritis and neuropsychiatric lupus are seldom drug-induced, though hydralazine and minocycline have been linked to occasional cases.[22] Hematologic abnormalities, such as leukopenia or anemia, may occur but are typically mild. Drug-specific clinical patterns are recognized in DIL. Procainamide-induced lupus frequently presents with serositis and constitutional symptoms, while hydralazine-induced lupus may feature rash, hepatosplenomegaly, lymphadenopathy, and, rarely, antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis with renal involvement.[23] Minocycline-induced lupus, most often seen in young women treated for acne, typically manifests with fever, arthralgia or arthritis, and rash, with occasional pneumonitis or cutaneous vasculitis. Autoantibody profiles in this setting frequently include antinuclear antibody (ANA), anti-double-stranded deoxyribonucleic acid antibody (dsDNA), and perinuclear ANCA (p-ANCA) positivity, with a lower prevalence of antihistone antibodies.[24] Anti-tumor necrosis factor (TNF) agents such as infliximab, adalimumab, and etanercept may induce ANA and anti-dsDNA positivity in up to 50% of patients, although fewer than 1% develop overt lupus. When DIL occurs with anti-TNF therapy, it is usually limited to cutaneous and serosal involvement, and antihistone antibodies are typically absent.[25] Interferons-α and -β, and immune checkpoint inhibitors have also been associated with lupus-like syndromes, most commonly presenting with cutaneous involvement.[26] A defining feature across all forms of DIL is the resolution of symptoms following discontinuation of the offending agent, typically within weeks to months. However, serologic abnormalities such as ANA or anti-dsDNA may persist for years despite clinical improvement. This temporal relationship remains the most important diagnostic clue distinguishing DIL from idiopathic SLE.

The diagnostic evaluation of DIL largely parallels that of idiopathic SLE, but with a heightened focus on drug history and the temporal relationship between exposure and symptom onset. Symptoms often appear after months or years of continuous therapy. A detailed clinical assessment should include assessment for constitutional features such as low-grade fever, malaise, fatigue, anorexia, and weight loss, as well as musculoskeletal complaints (arthralgia, arthritis, myalgia), chest pain suggestive of pleuritis or pericarditis, and cutaneous manifestations such as photosensitive eruptions or rashes typical of SCLE.[1] Laboratory evaluation is essential, though findings may overlap with those seen in idiopathic SLE. A complete blood count, comprehensive metabolic panel, and urinalysis with urine sediment and quantitation of urinary protein are recommended.[5] Hematologic abnormalities occur less frequently than in SLE and are typically mild; leukopenia and thrombocytopenia are rare, whereas hemolytic anemia has been reported with methyldopa and procainamide.[6] Liver enzyme abnormalities may occur in up to half of patients with minocycline-induced lupus.[24] Autoantibody testing provides key diagnostic information in suspected DIL. ANA is positive in nearly all cases, typically displaying a homogeneous pattern, although a speckled pattern may also occur. Antihistone antibodies are the most characteristic marker, present in more than 95% of patients with hydralazine-, procainamide-, quinidine-, or chlorpromazine-induced lupus. However, they are less consistently observed with medications such as minocycline, propylthiouracil, and statins. Their specificity is limited, as antihistone antibodies may also be detected in up to 80% of idiopathic SLE cases.[27] Anti-dsDNA antibodies are generally absent in classic DIL caused by procainamide or hydralazine, but may appear in lupus induced by anti-TNF agents or interferon-α. When present, they are often immunoglobulin (Ig) M subtype, in contrast to the IgG predominance observed in idiopathic lupus.[28] Anti-Ro/SSA antibodies are strongly associated with drug-induced SCLE and are detected in over 80% of cases.

Anti-dsDNA antibodies are generally absent in classic DIL caused by procainamide or hydralazine, but may appear in lupus induced by anti-TNF agents or interferon-α. When present, they are often immunoglobulin (Ig) M subtype, in contrast to the IgG predominance observed in idiopathic lupus.[28] Anti-Ro/SSA antibodies are strongly associated with drug-induced SCLE and are detected in over 80% of cases. In contrast, anti–Smith antibody and anti–ribonucleoprotein antibody antibodies are rarely positive, which helps distinguish DIL from idiopathic disease.[9] ANCA should be assessed in patients exposed to hydralazine, minocycline, methimazole, or propylthiouracil, given the potential overlap between DIL and drug-induced ANCA-associated vasculitis.[23] Detecting ANCA positivity in this context may help identify patients at risk for more severe vasculitic manifestations and guide appropriate monitoring and management. Histopathologic evaluation of skin lesions, as previously noted, cannot reliably differentiate DIL from idiopathic SLE. Therefore, diagnosis relies on integrating clinical and serologic findings with a clear temporal relationship to the suspected medication and, critically, the resolution of symptoms following drug withdrawal. Clinical improvement usually occurs within weeks to months, while autoantibodies, particularly ANA, often persist long after symptom resolution. In drug-induced SCLE, diagnosis is supported when characteristic cutaneous lesions develop within 1 to 5 months of exposure to a known trigger medication, occur in association with anti-Ro/SSA positivity, and improve after discontinuation of the offending agent. Compared to idiopathic SCLE, drug-induced forms often present with widespread distribution, a feature that should raise suspicion for a medication-related etiology.[9]

The cornerstone of management is prompt discontinuation of the suspected medication. Most patients experience symptom resolution, though improvement may take several months, depending on the drug, disease manifestations, and individual factors. Persistence of symptoms despite withdrawal should prompt consideration of underlying idiopathic SLE that may have been unmasked. Rechallenge with the offending agent is not recommended.[9] Treatment of residual or bothersome manifestations is guided by principles used in idiopathic SLE or SCLE: nonsteroidal anti-inflammatory drugs may be used for arthralgia or arthritis. Hydroxychloroquine can be considered for persistent musculoskeletal, cutaneous, or constitutional symptoms not resolving within 4 to 8 weeks of drug withdrawal. Low-dose systemic glucocorticoids may be used temporarily for moderate pleurisy or pericarditis, with rapid symptom improvement expected; higher doses are rarely necessary. Topical corticosteroids are effective for cutaneous disease, whereas more refractory cases may warrant therapy with antimalarials, methotrexate, or mycophenolate mofetil.[1] Severe organ involvement, like nephritis or serositis related to hydralazine or anti-TNF agents, should be managed with SLE-based immunosuppressive regimens in addition to withdrawal of the causative agent.[29] In anti-TNF–induced lupus, most patients experience improvement after discontinuation of the offending agent. Recent observational data suggest that in selected cases with mild manifestations, patients may be able to switch to another biologic, either within or outside the TNF inhibitor class, under close clinical monitoring. However, such decisions should be approached cautiously, given the limited evidence base and the need for individualized risk-benefit assessment and shared decision-making.[30] Autoantibody titers (eg, ANA, antihistone antibodies) often remain positive long after clinical resolution and therefore should not be used to guide therapy. The patient's clinical course should inform management decisions.[27]

The differential diagnosis of DIL is broad and largely overlaps with idiopathic SLE and idiopathic SCLE. Distinguishing among these conditions is essential because management strategies and prognosis differ. Idiopathic SLE is more likely to present with features uncommon in DIL, including renal and neurologic involvement, severe hematologic abnormalities, and chronic cutaneous disease. The presence of high-titer anti-dsDNA or anti-Smith antibodies, low complement levels, or persistence of symptoms despite withdrawal of the suspected medication favors a diagnosis of idiopathic SLE or the unmasking of preexisting idiopathic SLE, rather than true DIL.[29] Similarly, idiopathic SCLE must be considered in patients presenting with widespread annular or papulosquamous eruptions. However, drug-induced SCLE is more likely to exhibit a broader distribution, occasionally with bullous or vasculitic features, and is frequently associated with anti-Ro/SSA antibodies that often normalize after discontinuation of the offending drug.[9] Another essential consideration is drug-induced ANCA-associated vasculitis, particularly in patients exposed to agents such as hydralazine, minocycline, and propylthiouracil. Unlike classic DIL, drug-induced ANCA-associated vasculitis typically presents with more severe renal involvement, often manifesting as necrotizing glomerulonephritis, and may necessitate immunosuppressive therapy in addition to withdrawal of the offending agent. ANCA positivity, typically perinuclear, further supports this diagnosis.[31] Finally, a variety of other disorders may mimic aspects of drug-induced lupus. Photodistributed dermatoses such as polymorphic light eruption, dermatomyositis, and drug eruptions can resemble cutaneous lupus. In contrast, systemic autoimmune diseases such as rheumatoid arthritis, systemic sclerosis, psoriasis, and Sjögren syndrome may share overlapping musculoskeletal or constitutional symptoms. In patients receiving biologic therapies, particularly anti–TNF agents, infection must also be excluded, as opportunistic infections may present with fever, rash, and arthritis and closely resemble drug-induced lupus.

DIL generally carries an excellent prognosis. Most patients experience improvement within weeks of discontinuing the offending drug. However, cutaneous or musculoskeletal symptoms may persist for several months and may require nonsteroidal anti-inflammatory drugs, hydroxychloroquine, or short courses of glucocorticoids. Severe organ involvement is rare; when present, it often suggests underlying idiopathic SLE unmasked by drug exposure. Autoantibodies, particularly ANA and antihistone, may remain positive long after clinical resolution but do not indicate ongoing disease. In patients with idiopathic SLE, drugs such as TNF inhibitors may induce autoantibody formation in up to half of cases; however, clinical manifestations are usually mild, and careful monitoring rather than avoidance is recommended.[7] With timely recognition and prompt withdrawal of the offending agent, long-term outcomes are highly favorable, and relapse is uncommon.

Most patients with DIL do not develop complications, and long-term outcomes are generally excellent. Rare cases of renal involvement, particularly those associated with hydralazine or anti–TNF agents, may require treatment with corticosteroids and additional immunosuppressive agents. Even in these cases, progression to permanent renal damage is uncommon, and complete resolution is expected following withdrawal of the offending drug and appropriate management.[22]

Patients starting new medications should be counseled about the risks of both common and rare adverse effects. As DIL is an uncommon reaction to many widely used and less frequently prescribed drugs, it is often not recognized as a potential adverse effect. This underscores the need for vigilance by patients and caregivers in reporting new or unusual symptoms to prescribing and frontline providers. Additionally, because DIL may take weeks to months to manifest, the temporal association between a medication and symptom onset may not be immediately apparent. Maintaining a complete medication history and timeline is essential, enabling clinicians to assess the likelihood that a specific drug is contributing to a patient's presentation.

Key facts to keep in mind about DIL include the following: DIL accounts for up to 10% of new lupus cases annually. Symptoms usually begin weeks to months after starting the offending drug. Most cases involve mild disease; major organ involvement is uncommon. Common features include fever, fatigue, arthralgia/arthritis, myalgia, and serositis. Cutaneous findings may include SCLE-type rashes; discoid lesions are rare ANA is positive in nearly all cases, often in a homogeneous pattern. Antihistone antibodies are strongly associated with classic DIL (>95% in hydralazine, procainamide, quinidine, chlorpromazine). Anti-dsDNA antibodies are usually absent in classic DIL, but may be present in anti-TNF–induced lupus (often IgM). Anti-Ro/SSA antibodies are common in drug-induced SCLE. Anti-Sm and anti-RNP antibodies are rarely seen. ANCA testing is essential in patients exposed to hydralazine, minocycline, propylthiouracil, or methimazole. High-risk drugs include procainamide and hydralazine. Other implicated drugs include isoniazid, minocycline, quinidine, rifampin, methyldopa, carbamazepine, ethosuximide, chlorpromazine, PTU, sulfasalazine, and interferon-α. All TNF inhibitors (etanercept, infliximab, adalimumab, golimumab, certolizumab) can cause DIL; <1% develop true clinical lupus. Immune checkpoint inhibitors may cause SCLE or SLE-like disease. Slow acetylators have an increased risk, especially with procainamide and hydralazine. Histology of skin lesions resembles idiopathic lupus and cannot distinguish DIL. Treatment begins with stopping the offending drug. Symptoms usually resolve within weeks to months after discontinuation. Autoantibodies may remain positive long after clinical improvement. Rechallenge with the offending drug is not recommended. Severe organ involvement suggests unmasking of idiopathic SLE rather than true DIL.

Managing DIL underscores the importance of effective interprofessional collaboration in delivering safe, patient-centered care. Front-line clinicians in primary and urgent care settings play a critical role in recognizing symptoms, evaluating complex clinical presentations, and formulating individualized management plans. Collaboration with specialists, such as dermatology and rheumatology, is essential for interpreting diagnostic tests, refining differential diagnoses, and confirming the diagnosis of DIL. Nurses contribute through ongoing monitoring, reinforcement of patient education, and serving as key liaisons between patients and clinicians. Pharmacists enhance safety by reviewing medication regimens, identifying potential culprit drugs, and recommending appropriate alternatives. Laboratory specialists and allied health professionals support accurate diagnostic testing and follow-up, helping to ensure timely recognition and coordinated management of DIL. Ethical responsibilities include ensuring timely recognition of DIL, avoiding unnecessary treatments, and promoting patient safety through transparent communication. Strategies such as shared electronic health records, interprofessional case reviews, and coordinated care plans foster accountability and reduce misdiagnosis. Open communication flattens hierarchy and empowers each team member to contribute observations, such as subtle symptom changes in medication history, that may be critical to accurate diagnosis and management. By integrating these skills and responsibilities, the healthcare team improves outcomes by facilitating early recognition of DIL, prompt withdrawal of the offending drug, appropriate management of complications, and coordinated follow-up. This interprofessional approach not only enhances patient safety and clinical results but also strengthens team performance and continuity of care.